Literature DB >> 12824046

N- and C-terminal modifications of negamycin.

B Raju1, Kathleen Mortell, Sampathkumar Anandan, Hardwin O'Dowd, Hongwu Gao, Marcela Gomez, Corinne Hackbarth, Charlotte Wu, Wen Wang, Zhengyu Yuan, Richard White, Joaquim Trias, Dinesh V Patel.   

Abstract

Negamycin 1 is a bactericidal antibiotic with activity against Gram-negative bacteria, and served as a template in an antibiotic discovery program. An orthogonally protected beta-amino acid derivative 3a was synthesized and used in parallel synthesis of negamycin derivatives on solid support. This advanced intermediate was also used for N- and C-terminal modifications using solution-phase methodologies. The N-terminal modifications have resulted in the identification of active analogues, whereas the C-terminal modifications resulted in complete loss of antibacterial activity. The N-methyl negamycin analogue, 19a, inhibits protein synthesis (IC(50)=2.3 microM), has antibacterial activity (Escherichia coli, MIC=16 microgram/mL), and is efficacious in an E. coli murine septicemia model (ED(50)=16.3mg/kg).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824046     DOI: 10.1016/s0960-894x(03)00393-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Negamycin induces translational stalling and miscoding by binding to the small subunit head domain of the Escherichia coli ribosome.

Authors:  Nelson B Olivier; Roger B Altman; Jonas Noeske; Gregory S Basarab; Erin Code; Andrew D Ferguson; Ning Gao; Jian Huang; Manuel F Juette; Stephania Livchak; Matthew D Miller; D Bryan Prince; Jamie H D Cate; Ed T Buurman; Scott C Blanchard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit.

Authors:  Susan J Schroeder; Gregor Blaha; Peter B Moore
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

Review 3.  Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.

Authors:  Akihiro Taguchi; Keisuke Hamada; Yoshio Hayashi
Journal:  J Antibiot (Tokyo)       Date:  2017-09-27       Impact factor: 2.649

4.  Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens.

Authors:  David C McKinney; Gregory S Basarab; Alexis I Cocozaki; Melinda A Foulk; Matthew D Miller; Anatoly M Ruvinsky; Clay W Scott; Kumar Thakur; Liang Zhao; Ed T Buurman; Sridhar Narayan
Journal:  ACS Med Chem Lett       Date:  2015-07-12       Impact factor: 4.345

5.  Synthesis of cis- and trans-3-aminocyclohexanols by reduction of β-enaminoketones.

Authors:  Iris Montoya Balbás; Blanca Eda Domínguez Mendoza; Mario Fernández-Zertuche; Mario Ordoñez; Irma Linzaga-Elizalde
Journal:  Molecules       Date:  2011-12-27       Impact factor: 4.411

6.  The Antibiotic Negamycin Crosses the Bacterial Cytoplasmic Membrane by Multiple Routes.

Authors:  Daniel Hörömpöli; Catherine Ciglia; Karl-Heinz Glüsenkamp; Lars Ole Haustedt; Hildegard Falkenstein-Paul; Gerd Bendas; Anne Berscheid; Heike Brötz-Oesterhelt
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.